Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections

Ohsaki, Yoshinobu; Morita, Kazutoyo; Takeda, Hiroyuki; Kishino, Satoshi; Okumura, Shunsuke; Fujiuchi, Satoru

doi:10.1016/j.ijantimicag.2010.01.020

Cited by 7 publications

(1 citation statement)

References 13 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with evidence of its high efficacy against infections in dentistry, oral cavity surgery, and otorhinolaryngology [6]. By contrast, garenoxacin was able to maintain a high plasma concentration due to a long half-life [24], which probably contributed to its effectiveness in elderly patients with pneumonia. However, overall efficacy rates and efficacy rates in aspiration pneumonia of both drugs were comparable.…”

Section: Discussionsupporting

confidence: 86%

The efficacy and safety of sitafloxacin and garenoxacin for the treatment of pneumonia in elderly patients: A randomized, multicenter, open-label trial

Miyazaki

Nakamura

Hashiguchi

et al. 2019

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

Oral treatment for elderly outpatients with pneumonia is becoming increasingly important in this superaged society from the perspective of cost-effectiveness and limited hospital capacities. We evaluated the efficacy and safety of two oral respiratory quinolones, sitafloxacin and garenoxacin, in elderly patients with pneumonia. This randomized, multicenter, open-label trial was conducted among patients aged !65 years with clinically and radiographically confirmed pneumonia in Japan. Patients were randomly assigned (1:1) to receive either sitafloxacin (100 mg/day) or garenoxacin (400 mg/day) for 3e10 days. The primary efficacy endpoint was the clinical cure rate at 5e10 days after the end of treatment. From December 2013 to November 2017, we enrolled 120 patients at 11 hospitals and randomly assigned 59 patients to the sitafloxacin group (1 patient withdrew) and 61 patients to the garenoxacin group. These included 30 patients with nursing and healthcare-associated pneumonia (NHCAP) (18 receiving sitafloxacin, 12 receiving garenoxacin) and 37 patients with aspiration pneumonia (16 receiving sitafloxacin, 21 receiving garenoxacin). The clinical cure rates in the sitafloxacin and garenoxacin groups were 88.5% (95% confidence interval: 76.6e95.6) and 88.9% (95% confidence interval: 77.4e95.8), respectively. No significant differences were observed in the incidence rates of drug-related adverse events between the sitafloxacin (20.7%; 12/58 patients) and garenoxacin (27.9%; 17/61 patients) groups. The most common adverse event was hepatic dysfunction, which occurred in seven patients in each group. We conclude

show abstract

Section: Discussionsupporting

confidence: 86%